omega-n-methylarginine has been researched along with bibp 3226 in 1 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (bibp 3226) | Trials (bibp 3226) | Recent Studies (post-2010) (bibp 3226) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 248 | 0 | 54 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | bibp 3226 (IC50) |
|---|---|---|---|
| Neuropeptide Y receptor type 1 | Homo sapiens (human) | 0.0091 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, GG; Hotta, Y; Ishikawa, A; Ishikawa, N; Kurimoto, N; Nan, YS; Nishiwaki, K; Shigei, T; Shimada, Y | 1 |
1 other study(ies) available for omega-n-methylarginine and bibp 3226
| Article | Year |
|---|---|
Neuropeptide Y enhances permeability across a rat aortic endothelial cell monolayer.
Topics: Animals; Anti-Anxiety Agents; Aorta; Arginine; Bradykinin; Bradykinin B2 Receptor Antagonists; Capillary Permeability; Cells, Cultured; Cyclic AMP; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Histamine; Indomethacin; Male; Neuropeptide Y; Nitric Oxide; omega-N-Methylarginine; Peptide Fragments; Peptide YY; Rats; Rats, Wistar; Receptors, Neuropeptide Y; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2004 |